ILCA 2024 | Dr. Zilin Cui: Milan Criteria vs. Ontario Criteria—A UNOS Analysis

ILCA 2024 | Dr. Zilin Cui: Milan Criteria vs. Ontario Criteria—A UNOS Analysis

In clinical practice, several criteria are available for evaluating liver transplant candidates, such as the Milan Criteria, UCSF Criteria in the U.S., Ontario Criteria in Canada, and domestic standards like the Fudan Criteria and Hangzhou Criteria in China. Among these, the Milan Criteria are the most widely adopted. However, differences in survival outcomes based on these criteria suggest the need for refinement. At the recently held 2024 International Liver Cancer Association (ILCA) Conference, a study utilizing data from the United Network for Organ Sharing (UNOS) compared survival rates between patients evaluated under the Milan Criteria and the Ontario Criteria. Oncology Frontier invited Dr. Zilin Cui from Tianjin First Central Hospital to introduce and review the study.
Dr. Jiuda Zhao Publishes Breakthrough Study in JCO, Demonstrating Electroacupuncture’s Significant Impact on Triple Antiemetic Therapy for Highly Emetogenic Chemotherapy

Dr. Jiuda Zhao Publishes Breakthrough Study in JCO, Demonstrating Electroacupuncture’s Significant Impact on Triple Antiemetic Therapy for Highly Emetogenic Chemotherapy

Recently, the team led by Dr. Jiuda Zhao at the Breast Disease Diagnosis and Treatment Center of Qinghai University Affiliated Hospital published their latest research findings in the Journal of Clinical Oncology (JCO), with an impact factor of 42.10. This study is the first to combine the current standard triple antiemetic therapy with electroacupuncture (EA) to address chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients. The results demonstrate that adding EA to the standard triple antiemetic regimen significantly enhances CINV treatment outcomes. This study stands as the highest-impact acupuncture-related research publication in the field of oncology in China, showcasing the scientific prowess and innovative capabilities of Chinese scholars on the international stage. Oncology Frontier invited Dr. Jiuda Zhao to discuss this groundbreaking study.
CAR-T vs. Bispecific Antibodies: Dr. Junmin Song’s Groundbreaking Myeloma Study at ESMO 2024

CAR-T vs. Bispecific Antibodies: Dr. Junmin Song’s Groundbreaking Myeloma Study at ESMO 2024

The 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) was recently held in Barcelona, Spain. As one of the premier global oncology conferences, it brought together experts and scholars from around the world to share cutting-edge research and chart future directions. During the conference, Dr. Junmin Song from the Jacobi Medical Center, Albert Einstein College of Medicine, presented the first real-world study comparing BCMA CAR-T therapy with bispecific antibodies in the treatment of multiple myeloma (802MO). This presentation garnered significant attention from attendees. Hematology Frontier invited Dr. Song to provide an in-depth interpretation of the study and to discuss the future prospects of these two innovative therapies in multiple myeloma treatment.
CSCO 2024: Dr. Jun Zhu Spearheads China’s Breakthroughs in Anti-Tumor Drug Development

CSCO 2024: Dr. Jun Zhu Spearheads China’s Breakthroughs in Anti-Tumor Drug Development

From September 25 to 29, 2024, the 27th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was successfully held in Xiamen. Themed Patient-Centered, Sharing the Future, the conference brought together major research advancements and developments from both domestic and international spheres. Over the past two decades, CSCO has been a continuous leader in the development of clinical oncology in China, with numerous experts and scholars contributing to and benefiting from CSCO’s growth. In response to CSCO's initiative, Hematology Frontier established the Growing with CSCO column to look back at the history of this organization alongside Chinese scholars. This issue features an exclusive interview with Dr. Jun Zhu, Vice President of the CSCO Council and Professor at Peking University Cancer Hospital, where he shares his journey of growing with CSCO and highlights the progress and achievements in the field of lymphoma in China.
Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future

Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future

Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future Editor's Note: From September 22nd to 24th, 2024, the 20th International Esophageal Cancer Conference (ISDE) took place in Edinburgh, Scotland. The Neo-AEGIS study, which compared the efficacy of perioperative chemotherapy with the CROSS regimen (preoperative chemotherapy combined with radiotherapy) in the treatment of esophageal cancer, captured global attention. As the corresponding author of the study, Dr. John Reynolds from St. James's Hospital in Ireland provided an in-depth interpretation of the research findings and discussed their profound impact on future strategies for esophageal cancer treatment.
CSCO 2024 Visionary: Dr. Jun Zhou Illuminates the Path Forward for Biliary Tract Cancer Treatment

CSCO 2024 Visionary: Dr. Jun Zhou Illuminates the Path Forward for Biliary Tract Cancer Treatment

From September 25 to 29, 2024, the highly anticipated 27th National Clinical Oncology Conference and CSCO Annual Meeting was successfully held in Xiamen. This prestigious event brought together top experts in the field of oncology from across China, focusing on standardized pathways for diagnosis and treatment of malignant tumors and exploring the latest frontiers. During the conference, Dr. Jun Zhou from Peking University Cancer Hospital delivered a presentation titled “Advances in the Application of New Anticancer Drugs in Biliary Tract Cancer” at the dedicated session on targeted therapy for cholangiocarcinoma. Oncology Frontier had the opportunity to conduct an in-depth interview with Professor Zhou, delving into the current progress in drug treatments for biliary tract cancers and exploring future research directions.
CUA 2024 | Dr. Jeremy Teoh: Addressing Unmet Needs in NMIBC and Exploring Advanced Diagnostic and Treatment Strategies

CUA 2024 | Dr. Jeremy Teoh: Addressing Unmet Needs in NMIBC and Exploring Advanced Diagnostic and Treatment Strategies

Bladder cancer is one of the most common malignant tumors among the Chinese population, with 75% of cases classified as non-muscle invasive bladder cancer (NMIBC), which has a high postoperative recurrence rate. What are the unmet diagnostic and treatment needs of NMIBC patients? Which research findings may change future clinical practice for NMIBC? During the recent CUA Annual Meeting, Urology Frontier invited Dr. Jeremy Teoh from The Chinese University of Hong Kong to discuss the current unmet needs in NMIBC, the factors influencing recurrence, and the latest research developments that could potentially change clinical practice.
WCLC 2024丨Furmonertinib Blazes New Trail in EGFR PACC NSCLC: A Quantum Leap in Precision Oncology

WCLC 2024丨Furmonertinib Blazes New Trail in EGFR PACC NSCLC: A Quantum Leap in Precision Oncology

EGFR P-loop-aC helix compression (PACC) mutation is a recently identified subtype of EGFR mutations in non-small cell lung cancer (NSCLC), and its potential for precision therapy had not been clinically validated until now. At the 2024 World Conference on Lung Cancer (WCLC 2024), during the Presidential Symposium Presentation, the global phase Ib FURTHER trial's proof-of-concept results were revealed. Furmonertinib as monotherapy in first-line treatment of NSCLC patients with EGFR PACC mutations demonstrated outstanding efficacy and safety. Oncology Frontier  interviews the study’s principal investigator, Dr. Xiuning Le from the MD Anderson Cancer Center, to delve into how EGFR PACC mutations moved from concept to clinic and how Furmonertinib is pioneering targeted therapy for this subtype of lung cancer.